SUNNYVALE, Calif., April 14, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced that it will report results for its third quarter of fiscal 2011, ended March 31, 2011 on Thursday, May 5, 2011 after the market closes.

A conference call to review the results will begin at 2:00 p.m. PT/5:00 p.m. ET and will be hosted by Euan S. Thomson, Ph.D., president and chief executive officer and Derek Bertocci, senior vice president and chief financial officer.

The conference call dial-in numbers are 1-866-578-5784 (USA) or 1-617-213-8056 (International), Conference ID: 59351513. In addition, a dial-up replay of the conference call will be available beginning May 5, 2011 at 5:00 p.m. PT/8:00 p.m. ET and ending on May 8, 2011. The replay telephone number is 1-888-286-8010 (USA) or 1-617-801-6888 (International), Conference ID: 19680048.

A live webcast of the call will also be available from the Investor Relations section of the corporate Web site at http://www.accuray.com. A webcast replay can be accessed on the corporate Web site beginning Thursday, May 5, 2011 at approximately 5:00 p.m. PT/8:00 p.m. ET. The replay will remain available until Accuray announces its results for the fourth quarter of fiscal 2011, ending June 30, 2011.

About the CyberKnife® Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 100,000 patients worldwide and currently more than 222 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com. 

SOURCE Accuray Incorporated